兽医再生医学市场 - 按动物类型、产品类型、应用、最终用户 - 全球预测

由于动物慢性疾病和骨科问题的盛行率不断增加，2024年至2032年兽医再生医学市场的复合年增长率预计将达到9.9%。随着宠物数量的增加，对先进兽医解决方案的需求激增。据美国宠物产品协会称，到 2022 年，68% 的美国家庭拥有宠物。这些疗法可以改善宠物的生活品质并延长它们的寿命。

生物技术的进步和研发投资的增加也推动了市场的成长。研究机构、兽医诊所和製药公司之间的合作正在开发有效的再生疗法。例如，《兽医科学杂誌》2023 年的一项研究强调，接受干细胞疗法治疗的狗的骨关节炎症状改善了 20%。监管部门对新疗法的批准以及兽医专业人员对再生医学益处的认识不断提高，有利于新疗法的采用。个人化医疗和创新给药系统的趋势提高了治疗效果和可及性，塑造了产业前景。

整个兽医再生医学行业根据动物类型、产品类型、应用、最终用户和地区进行分类。

生物治疗领域预计到 2032 年将实现强劲成长，这主要是由于这些治疗方法的功效和创新性质。生物疗法因其再生能力和治疗各种动物疾病的潜力而被利用，例如肌肉骨骼损伤、伤口癒合和慢性发炎性疾病。这些疗法利用人体的自​​然癒合过程，为传统疗法提供微创且高效的替代方案。越来越多的临床证据支持生物疗法的安全性和有效性，加上研发投资的不断增加，正在推动生物疗法在兽医实践中的采用。

由于宠物和牲畜中受伤和外科手术的发生率不断增加，到 2032 年，创伤/伤口护理应用领域将占据显着的行业份额。干细胞治疗和富血小板血浆 (PRP) 等再生疗法可加速癒合、减少发炎并最大限度地减少疤痕。这些先进的疗法提供了比传统疗法更有效、侵入性更小的替代方案，从而改善动物的治疗结果并加快恢復时间。兽医和宠物主人越来越意识到再生医学对创伤和伤口护理的好处，加上治疗方法和产品可用性的不断进步，正在推动这一领域的扩张。

亚太地区兽医再生医学市场预计到 2032 年将大幅成长。宠物主人和兽医越来越意识到干细胞治疗和组织工程等再生疗法的好处。此外，对兽医医疗基础设施的大量投资和可支配收入的增加使人们能够更多地获得这些创新疗法。在学术机构和生物技术公司之间合作的支持下，该地区对研发的高度重视正在进一步加速在整个亚太地区引入新型动物再生医学。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性和退化性疾病的发生率上升
    • 再生医学不断进步
    • 增加研发投入和活动
    • 宠物拥有量和支出不断成长
  • 产业陷阱与挑战
    • 治疗的不良反应
    • 监管挑战
• 成长潜力分析
• 监管环境
• 未来市场趋势
• 按国家/地区分類的宠物数量
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按动物类型，2021 - 2032 年

• 主要趋势
• 伴侣动物
• 畜牧动物

第 6 章：市场估计与预测：按产品类型，2021 - 2032 年

• 主要趋势
• 干细胞治疗
  • 自体
  • 同种异体
• 生物疗法
  • 富血小板血浆 (PRP)
  • 生长因子
• 组织工程

第 7 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 骨科
• 创伤/伤口护理
• 其他应用

第 8 章：市场估计与预测：按最终用户划分，2021 - 2032 年

• 主要趋势
• 兽医院
• 兽医诊所
• 学术界及研究机构

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Animal Cell Therapies, Inc.
• Ardent
• Bioceltix
• Boehringer Ingelheim International GmbH
• CTSL (Cell Therapy Sciences)
• Dechra
• Enso Discoveries
• Magellan Stem Cells
• Medrego
• Regeneus Ltd (Cambium Bio Ltd.)
• StemcellX
• VetStem, Inc.
• Zoetis Inc.

The veterinary regenerative medicine market is poised to record 9.9% CAGR during 2024-2032, due to the increasing prevalence of chronic ailments and orthopedic issues in animals. With pet ownership rising, the demand for advanced veterinary solutions has surged. According to the American Pet Products Association, 68% of U.S. households owned a pet in 2022. Regenerative medicine, including stem cell therapy and tissue engineering, offers treatments for conditions like osteoarthritis, tendon injuries, and cardiac diseases in animals. These therapies improve pets' quality of life and extend their lifespans.

Advancements in biotechnology and increased R&D investments are also driving the market growth. Collaborations between research institutions, veterinary clinics, and pharmaceutical companies are developing effective regenerative therapies. For instance, a 2023 study by the Journal of Veterinary Science highlighted a 20% improvement in osteoarthritis symptoms in dogs treated with stem cell therapy. Regulatory approvals for new treatments and growing awareness among veterinary professionals about regenerative medicine's benefits are favoring adoption. The trend towards personalized medicine and innovative delivery systems enhances treatment efficacy and accessibility, shaping the industry outlook.

The overall veterinary regenerative medicine industry is classified based on animal type, product type, application, end-user, and region.

The biological therapy segment is slated to record robust growth through 2032, primarily due to the efficacy and innovative nature of these treatments. Biological therapies are utilized for their regenerative capabilities and potential to treat a variety of animal conditions such as musculoskeletal injuries, wound healing, and chronic inflammatory diseases. These therapies leverage the body's natural healing processes, offering a minimally invasive and highly effective alternative to traditional treatments. The growing body of clinical evidence supporting the safety and effectiveness of biological therapies, along with rising investment in R&D, is driving their adoption in veterinary practices.

The trauma/wound care application segment will register notable industry share by 2032, due to the increasing prevalence of injuries and surgical procedures among pets and livestock. Regenerative therapies, such as stem cell treatments and platelet-rich plasma (PRP), accelerate healing, reduce inflammation, and minimize scarring. These advanced therapies provide a more effective and less invasive alternative to conventional treatments, leading to improved outcomes and faster recovery times for animals. The growing awareness among veterinarians and pet owners about the benefits of regenerative medicine for trauma and wound care, coupled with ongoing advancements in treatment methodologies and product availability, is driving the expansion of this segment.

Asia Pacific veterinary regenerative medicine market is poised for substantial growth through 2032. Increasing pet ownership, especially in urban areas, is contributing to a rising demand for advanced veterinary care solutions. There is growing awareness among pet owners and veterinarians about the benefits of regenerative therapies, such as stem cell treatments and tissue engineering. Additionally, significant investments in veterinary healthcare infrastructure and rising disposable incomes are enabling greater access to these innovative treatments. The region's strong focus on R&D, supported by collaborations between academic institutions and biotechnology firms, is further accelerating the introduction of novel regenerative medicine for animals across Asia Pacific.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic and degenerative conditions
    • 3.2.1.2 Growing advancement in regenerative medicine
    • 3.2.1.3 Increasing R&D investment and activities
    • 3.2.1.4 Growing pet ownership and spendings
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects of the treatment
    • 3.2.2.2 Regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Pet population, by country
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Companion animals
• 5.3 Livestock animals

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Stem cell therapy
  • 6.2.1 Autologous
  • 6.2.2 Allogeneic
• 6.3 Biological therapy
  • 6.3.1 Platelet-rich plasma (PRP)
  • 6.3.2 Growth factors
• 6.4 Tissue engineering

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Orthopedics
• 7.3 Trauma/ wound care
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals
• 8.3 Veterinary clinics
• 8.4 Academics and research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Animal Cell Therapies, Inc.
• 10.2 Ardent
• 10.3 Bioceltix
• 10.4 Boehringer Ingelheim International GmbH
• 10.5 CTSL (Cell Therapy Sciences)
• 10.6 Dechra
• 10.7 Enso Discoveries
• 10.8 Magellan Stem Cells
• 10.9 Medrego
• 10.10 Regeneus Ltd (Cambium Bio Ltd.)
• 10.11 StemcellX
• 10.12 VetStem, Inc.
• 10.13 Zoetis Inc.